Analyst downgrades: MRK, AZN, MI, ONT and ZION
Posted Jul 7th 2008 11:44AM by Laurie Pasternack
Filed under: Analyst reports, Analyst upgrades and downgrades, Merck and Co (MRK)
MOST NOTEWORTHY: Merck, On2 Technologies and Zions Bancorp were today's noteworthy downgrades:
- UBS downgraded Merck & Co Inc (NYSE: MRK) to Neutral from Buy citing slowing Gardasil trends and vaccine supply issues.
- Merriman cut On2 Technologies Inc (AMEX: ONT) to Neutral from Buy to reflect the reduced visibility into financials and management changes.
- Baird downgraded shares of Zions Bancorporation (NASDAQ: ZION) to Neutral from Outperform to reflect deteriorating credit quality and growing capital concerns. The firm lowered their target price to $32 from $43.
OTHER DOWNGRADES:
Tags: Acme Packet, AcmePacket, APKT, AstraZeneca, AZN, downgrades, Gardasil, inthenews, Marshall Ilsley, MarshallIlsley, Merck, Merck co, MerckCo, MI, MRK, On2, On2 Tech, On2 Technologies, On2Tech, On2Technologies, ONT, ZION, ZIons Bancorp, ZionsBancorp